Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198105 | 0.86 | NPC1 (0.49) | ALDH1A1PKMMCOLN3NPC1GAA | |
| SCHEMBL4199654 | 0.85 | NPC1 (0.50) | ALDH1A1PKMMCOLN3NPC1GAA | |
| SCHEMBL4189902 | 0.82 | NPC1 (0.45) | ALDH1A1PKMMCOLN3NPC1GAA | |
| Cyclohexanol SCHEMBL4190330 | 0.81 | NPC1 (0.50) | ALDH1A1PKMMCOLN3NPC1GAA | |
| SCHEMBL4201610 | 0.80 | PKM (0.44) | ALDH1A1PKMMCOLN3NPC1GAA | |
| SCHEMBL4202523 | 0.80 | PKM (0.51) | ALDH1A1PKMMCOLN3NPC1GAA | |
| SCHEMBL4195126 | 0.79 | NPC1 (0.44) | ALDH1A1PKMMCOLN3NPC1GAA | |
| SCHEMBL4189973 | 0.79 | PKM (0.42) | ALDH1A1PKMMCOLN3NPC1GAA | |
| SCHEMBL4194027 | 0.79 | PKM (0.52) | ALDH1A1PKMNPC1GAAKDM4E | |
| SCHEMBL4190323 | 0.78 | NPC1 (0.47) | ALDH1A1PKMMCOLN3NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | claimed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | ALDH1A1 2744/4885PKM 1855/4885MCOLN3 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.